From its beginning, CATIE has shared information with people living with HIV so that they can take better care of their health. In Fall 2015, we undertook a national online survey to better understand the information needs of people living with HIV today. The survey results may confirm what you already know about your clients’ information needs. Or perhaps they contain a surprise or two. Whatever the case, the results help guide all of us in how we can best serve our clients.
L’AFRAVIH est une conférence scientifique, organisée tous les deux ans par l’Alliance francophone des acteurs de santé contre le VIH. Elle avait lieu cette année du 20 au 23 avril à Bruxelles, rassemblant plus d’un millier de participants, venus d’Europe, d’Afrique, d’Asie ou d’Amérique du Nord. L’AFRAVIH ouvre un espace de débat francophone unique pour les acteurs de la lutte contre le VIH et les hépatites virales. La conférence est l’occasion de discuter avec des intervenants très divers, issus du milieu communautaire, de la recherche ou de la santé publique. Difficile de faire le tri dans un programme aussi riche… Mais voici trois points à retenir de la conférence!
The administration of naloxone, a chemical compound that effectively temporarily reverses the effects of an opioid overdose, is recommended by the World Health Organization to be used in the case of an opioid overdose. Naloxone is currently available in Canada only in an injectable form and by prescription only; it can only be administered to the person named on the prescription, not to a third party. With the objective of making naloxone more widely available in Canada to address the growing number of opioid overdoses, and consequent on a review of health and safety data, Health Canada has suggested an amendment to the prescription drug list to allow non-prescription use of naloxone specifically for emergency use for opioid overdose outside hospital settings. A public consultation on the proposal has been initiated and if the change in status continues to be supported by consultation evidence, the change will be finalized.
Lesbian, bisexual and queer women are rarely included in HIV research. Women who have sex with women, and their HIV infection rates, are not captured anywhere because women cannot report having a woman as a sexual partner in Canada’s HIV statistics. The current record only allows women to report HIV exposure either through injection drug use or heterosexual sex. This contributes to the erasure of women’s sexual and gender diversity and fluidity in HIV research. Queer* women are ignored in HIV research: this is a problem and here is why it matters.
The CATIE Blog hosts the views and opinions of people and organizations working and volunteering in Canada’s response to HIV and hepatitis C.